Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

News & Events

Genomic analysis and biorepository research study takes aim at metastatic bladder cancer

Hoosier Cancer Research Network is partnering with the Bladder Cancer Advocacy Network (BCAN) to conduct a large-scale bladder cancer genomic analysis and biorepository research study.

Known as UC-GENOME (HCRN GU15-217), the research study is the first project of the Bladder Cancer Genomics Consortium (BCGC), a collaborative effort between BCAN and major medical centers. The BCGC’s goal is to develop an enriched understanding of the genomic profile of bladder cancer to facilitate the development of novel therapeutics.

The research study is open to accrual at the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, N.C. Additional sites are expected to open soon. Read More

HCRN study tests mFOLFIRINOX combined with ramucirumab in advanced pancreatic cancer

Researchers investigating many types of cancers have celebrated significant breakthroughs over the years. Yet, some cancers lag well behind these successes.

Pancreatic cancer remains one of the most difficult to treat cancers. In 2016, about 53,000 new pancreatic cancer cases were diagnosed in the United States, and nearly 42,000 people died of their disease. Despite these statistics, there are glimmers of hope on the horizon.

Recent studies have shown that certain combination therapies can lead to improved outcomes over single agent therapy in pancreatic cancer. For example, a study of FOLFIRINOX (a combination of the drugs fluorouracil (5-FU), irinotecan, oxaliplatin, and leucovorin) was shown to improve one-year survival compared to gemcitabine alone.

As immunotherapies have gained prominence, pancreatic cancer researchers are now looking to take combination therapies to a new level. Read More

Study tests combination immunotherapy in advanced bile duct cancer

Cholangiocarcinoma, also known as bile duct cancer, is steadily rising in incidence worldwide. Symptoms often go undetected until the disease is far advanced. Surgical resection of tumors is considered the best approach toward attempting a cure, but less than half of patients whose tumors are surgically resected survive past five years, and those whose tumors are not surgically removed face a median survival time of just nine months.

A new Hoosier Cancer Research Network study may help researchers learn whether an investigational combination of immunotherapy drugs might lead to improvements in tumor response in cholangiocarcinoma patients who have received prior therapy for their cancer.

The study, known as HCRN GI16-263, is now open to accrual at the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C. Additional sites will open the study in the near future.

Read More

Study tests nivolumab, ipilimumab in treatment-naive kidney cancer

Hoosier Cancer Research Network (HCRN) announces the opening of a study for patients with advanced renal cell carcinoma who have not received prior treatment for their kidney cancer.

The phase II clinical trial, known as HCRN GU16-260, involves front-line therapy with nivolumab and salvage therapy with nivolumab and ipilimumab. The study may help researchers determine the activity of nivolumab, an agent already approved for patients with previously treated kidney cancer, in patients who have not received prior treatment.

Read More

HCRN study compares sequence of immunotherapy and anti-angiogenic drugs in metastatic kidney cancer

A new Hoosier Cancer Research Network study may help researchers learn whether the order in which two drugs are given has any effect on progression-free survival — the length of time it takes for cancer to grow or spread.

The randomized phase II study, known as HCRN GU15-223, will compare overall progression-free survival for two groups of subjects with metastatic renal cell carcinoma (kidney cancer). One group will receive first-line sunitinib, an anti-angiogenic drug, followed by second-line avelumab, an investigational immunotherapy drug. The other group will receive first-line avelumab followed by second-line sunitinib. Patients will have an equal chance of being randomized to either group.

Read More

IUSCC highlights HCRN, Big Ten CRC in visit with acting director of NCI

The Indiana University Melvin and Bren Simon Cancer Center hosted Doug Lowy, the acting director of the National Cancer Institute, for a full-day visit on June 28.

(Photo: Drs. Bryan Schneider (left) and Milan Radovich (middle) explain their work on the next generation of personalized medicine with Dr. Doug Lowy, acting director of the National Cancer Institute. Dr. Lowy visited the IU Simon Cancer Center on June 28. Photo credit: IU Simon Cancer Center)

In a series of small-group discussions in the morning, he met with cancer center members (members’ names appear in bold) and others to learn about:

  • Pediatric genomics with D. Wade Clapp, MD, and Jamie Renbarger, MD, MS
  • Breast cancer research program with Hari Nakshatri, PhD
  • Komen Tissue Bank at IU Simon Cancer Center with Anna Maria Storniolo, MD
  • Precision health with Bryan Schneider, MD, and Milan Radovich, PhD
  • Big Ten Cancer Research Consortium and the Hoosier Cancer Research Network with Bert O’Neil, MD, Cynthia Burkhardt, RN, and Chris Fausel, PharmD
  • Kenya and cancer with Patrick Loehrer, MD, Bob Einterz, MD, and Terry Vik, MD

In the afternoon, Dr. Lowy presented “NCI-supported Research: Concepts, Opportunities, and Applications” to cancer center members and others. Watch.

Read More

Richardson brings relentless dedication to patient care

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by Dr. William B. Fisher through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Each year the organization selects individuals for the award who exemplify the qualities Sandra possessed and respected in others, such as sustained professional commitment, contribution to the progress of oncology care, and the unflinching touch of compassion.

Stacey Richardson, RN, BSN, was honored as a recipient of the Sandra Turner Excellence in Clinical Research Award in 2016. Richardson is a clinical research coordinator with Community Health Network. Her story illustrates how a spark of compassion becomes a flame.

Read More

HCRN seeks Clinical Research Regulatory and Safety Associate

Hoosier Cancer Research Network (HCRN), a nonprofit cancer research organization in Indianapolis, is currently seeking a full-time Clinical Research Regulatory and Safety Associate.
Read More

Three HCRN studies accepted to ASCO 2017

Abstracts from three Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, June 2-6 at the McCormick Place in Chicago. The studies include LUN14-179 (poster session and discussion), GU14-206 (poster session and discussion), and GI14-186 (poster session). Read More

Gbolahan receives Fisher Young Investigator Award

Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Olumide Gbolahan, MD, as the 2016 recipient of the George and Sarah Jane Fisher Young Investigator Award.

Dr. Gbolahan grew up in Nigeria where his interest in medicine took root in high school. “My aptitude was really more toward the health sciences, biology core sciences,” he said. “I found myself moving in the direction of medicine. Once I found myself in medicine, I did not see that I could do anything else.” Read More

More News & Events →